TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04622735

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nefopam hydrochloride 30mg / paracetamol 500mg X2
Description: The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 500 Mg Oral Tablet X2
Description: The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam HCl 30 MG Oral Tablet X2
Description: The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
Study: NCT03427060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coversin
Description: Coversin - 22.5mg followed by 45mg for 6 months.
Study: NCT01843413

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo SRS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Description: Ancillary studies
Study: NCT06501040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based Educational Intervention
Description: View web-based educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Pre video baseline survey and a post video educational survey
Study: NCT03981796

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dostarlimab
Description: Participants will be administered dostarlimab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dostarlimab
Description: Participants will be administered dostarlimab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching dostarlimab
Description: Participants will be administered placebo matching dostarlimab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching dostarlimab
Description: Participants will be administered placebo matching dostarlimab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants will be administered carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Participants will be administered carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants will be administered carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Participants will be administered carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Participants will be administered paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Participants will be administered paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Participants will be administered paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Participants will be administered paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Participants will be administered niraparib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Niraparib
Description: Participants will be administered placebo matching Niraparib
Study: NCT02810353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Differential rapid maxillary expansion
Description: Twenty-five patients will be submitted to rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be provided by bands adapted either on the maxillary first permanent molars or on the second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. If the maxillary second deciduous molars will be banded, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars. Both anterior and posterior screws will be activated with a complete turn a day during 6 days. Then, only the anterior screw will be additionally activated for 4 more days. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rapid maxillary expansion
Description: Twenty-five patients will undergo rapid maxillary expansion using conventional Hyrax expander. Bands will be adapted either on the maxillary first permanent molars or on second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. Similarly to the experimental group, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars if the maxillary second deciduous molars will be banded. The expander screw will be activated with a complete turn a day during 6 days. After the expansion active phase, the screw will be fixed with acrylic resin and the appliance will be kept in the dental arch as a retainer for 6 months.
Study: NCT03961854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L. johnsonii Probiotic
Description: Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
Study: NCT00427960

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary advice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary advice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: rosuvastatin 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 10 mg
Study: NCT04282798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Music Intervention
Description: Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
Study: NCT01566760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fesoterodine fumarate
Description: one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
Study: NCT00772525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerispirdine
Description: form: tablet~Route: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerispirdine
Description: form: tablet~Route: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerispirdine
Description: form: tablet~Route: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: form: tablet~Route: oral
Study: NCT00882401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol (Vitamin D)
Description: ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo at same dose schedule as ergocalciferol
Study: NCT02389075

Intervention type: PROCEDURE
Intervention: Pinch biopsies
Description: Biopsies obtained during colonoscopy or flexible sigmoidoscopy.

Intervention type: PROCEDURE
Intervention: Pinch biopsies
Description: Biopsies obtained during colonoscopy or flexible sigmoidoscopy.

Intervention type: PROCEDURE
Intervention: Pinch biopsies
Description: Biopsies obtained during colonoscopy or flexible sigmoidoscopy.

Intervention type: PROCEDURE
Intervention: Flexible sigmoidoscopy
Description: Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
Study: NCT04205097

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine + glycopyrate
Description: maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2-4 mg/kg
Study: NCT01617148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
Study: NCT02722525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo treadmill stress CMR

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete treadmill exercise

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion Magnetic Resonance Imaging
Description: Undergo gadopentetate dimeglumine perfusion MRI

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete resistive lower extremity exercise

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spectroscopy
Description: Undergo skeletal muscle PMRS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00728052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
Study: NCT00772525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: form: tablet~Route: oral
Study: NCT00728052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules will be administered orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules will be administered orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules will be administered orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules will be administered orally with water.
Study: NCT02901639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling
Study: NCT01229397

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inflexal V
Description: vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V 0.5 mL administrated once only
Study: NCT04115540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS penile nerve stimulation
Description: The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum) to stimulate the penile nerves.
Study: NCT03127956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olumacostat Glasaretil Gel, 5.0%
Description: Gel containing Olumacostat Glasaretil
Study: NCT02145507

Intervention type: DRUG
Group type: OTHER
Intervention: SOLX (Investigational)
Description: SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.

Intervention type: DRUG
Group type: OTHER
Intervention: SOLX (Investigational)
Description: SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.

Intervention type: DRUG
Group type: OTHER
Intervention: AS-3 (Control)
Description: AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit
Study: NCT00772525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: form: tablet~Route: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: form: tablet~Route: oral
Study: NCT02145507

Intervention type: DRUG
Group type: OTHER
Intervention: AS-3 (Control)
Description: AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit
Study: NCT01960387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
Study: NCT00702572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
Description: This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which \<2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
Description: Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
Study: NCT00287079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®
Description: 44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: No Treatment
Description: No treatment for 96 weeks
Study: NCT02380820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airsoft Duo mattress
Description: A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airsoft Duo mattress
Description: A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Softform Premier mattress (in static mode)
Description: A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Softform Premier mattress (in static mode)
Description: A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
Study: NCT02001025

Intervention type: DEVICE
Intervention: Absorb scaffold

Intervention type: DEVICE
Intervention: Xience stent
Study: NCT05350735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm: SMS text reminders and medical card
Description: This study arm will assess compliance with anti-rabies vaccine regimen by participants in the presence of SMS text reminders as compared to without the SMS reminder.
Study: NCT01973543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VY-AADC01
Description: Neurosurgical delivery of VY-AADC01 to the brain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VY-AADC01
Description: Neurosurgical delivery of VY-AADC01 to the brain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VY-AADC01
Description: Neurosurgical delivery of VY-AADC01 to the brain.
Study: NCT04163718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: 800 mg Umbralisib will be self-administered on an outpatient basis. Umbralisib will be taken orally once daily within 30 minutes of a meal until removal from study. This treatment will be administered in 4 week (28-day) cycles.
Study: NCT02917473

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-person counseling
Description: In-person counseling~Sun protection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person counseling
Description: In-person counseling~Sun protection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written advice
Description: Written advice

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medical skin screening
Description: Medical skin screening
Study: NCT03717454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug treatment
Description: The medication will continue if DA causes tumors to shrink.
Study: NCT04212442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent Living Program for Affordable Housing.
Description: Two-month program intended to increase physical activity and function, including the following 4 steps:~1. Environmental and Policy Assessments: Nurse facilitator works with the affordable housing staff to identify and recommend feasible interventions to alter the environment, policy, and procedures to optimize resident function and physical activity.~2. Education: Nurse educates residents and study partners in the principles of the Independent Living Program, using established materials and adult learning techniques.~3. Establishing Resident Goals: The nurse completes Capability Assessment Forms and helps resident set goals to increase function and physical activity.~4. The nurse helps to motivate and mentor residents and study partners to achieve and maintain their goals, using evidence-based approaches.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent Living Program for Affordable Housing.
Description: Two-month program intended to increase physical activity and function, including the following 4 steps:~1. Environmental and Policy Assessments: Nurse facilitator works with the affordable housing staff to identify and recommend feasible interventions to alter the environment, policy, and procedures to optimize resident function and physical activity.~2. Education: Nurse educates residents and study partners in the principles of the Independent Living Program, using established materials and adult learning techniques.~3. Establishing Resident Goals: The nurse completes Capability Assessment Forms and helps resident set goals to increase function and physical activity.~4. The nurse helps to motivate and mentor residents and study partners to achieve and maintain their goals, using evidence-based approaches.
Study: NCT02917473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical skin screening
Description: Medical skin screening
Study: NCT06696807

Intervention type: DRUG
Intervention: glucocorticosteroids and/or intravenous immunoglobulin
Description: methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day
Study: NCT03136731

Intervention type: DIAGNOSTIC_TEST
Intervention: Celiac disease antibody screening
Description: Observational parameters
Study: NCT01606254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
Study: NCT01127204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZT-3TC-LPV/r twice a day
Description: AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
Study: NCT00430651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
Study: NCT03853798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: Participants will receive 5, 20, or 50 mg twice a day for up to 192 weeks (not including dose taper) unless the dose is modified for reasons related to safety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: Participants will receive 5, 20, or 50 mg twice a day for up to 192 weeks (not including dose taper) unless the dose is modified for reasons related to safety.
Study: NCT00430651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15